Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Complications Clear all
Completed Phase 4 Interventional

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

NCT00168857
View directory record Official record
Conditions
Hypertension, Diabetic Nephropathies
Interventions
telmisartan, losartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jun 11, 2026, 12:54 AM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NCT04567550
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 11, 2026, 12:54 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2005 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jun 11, 2026, 12:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344
View directory record Official record
Conditions
Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions
Standard, Standard-vaginal misoprostol
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

NCT02112071
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional Results available

Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)

NCT05439928
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
DEXCOM G6 CGM
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 11, 2026, 12:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

NCT02399826
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer; Diabetic
Interventions
Offloading, Dressing Application
Device · Procedure
Lead sponsor
Lower Extremity Institute for Research and Therapy
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
3
States / cities
Canfield, Ohio • Danville, Virginia • Troutville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics

NCT01371318
View directory record Official record
Conditions
Wounds, Diabetes Complications, Diabetic Foot, Foot Ulcer
Interventions
Online Wound Electronic Medical Record
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Tuscon, Arizona • Pomona, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jun 11, 2026, 12:54 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Jun 11, 2026, 12:54 AM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jun 11, 2026, 12:54 AM EDT
Recruiting Phase 4 Interventional

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

NCT05482789
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Exenatide
Drug
Lead sponsor
Maisa N. Feghali, MD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 11, 2026, 12:54 AM EDT
Recruiting No phase listed Observational

Mirragen Diabetic Foot Ulcer Study

NCT06598241
View directory record Official record
Conditions
Diabetic Foot Ulcer, Osteomyelitis Chronic
Interventions
Borate-base Bioactive Glass Fiber Matrix (BBGFM)
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 11, 2026, 12:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes

NCT00585494
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Complications
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jun 11, 2026, 12:54 AM EDT
Recruiting Not applicable Interventional

Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs

NCT06560502
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer
Interventions
Standard of Care-DFU, AmnioCore - DFU, Amnio Quad-Core - DFU, Standard of Care-VLU, Amnio Tri-Core - VLU, Amniocore Pro +
Other
Lead sponsor
Stability Biologics
Industry
Eligibility
21 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 11, 2026, 12:54 AM EDT
Recruiting Not applicable Interventional

Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes

NCT06867861
View directory record Official record
Conditions
Gestational Diabetes Mellitus (GDM)
Interventions
Fiber
Dietary Supplement
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Early Phase 1 Interventional

Photobiomodulation for the Treatment of Diabetic Macular Edema

NCT02457975
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jun 11, 2026, 12:54 AM EDT
Terminated Phase 3 Interventional Results available

PROMINENT-Eye Ancillary Study (Protocol AD)

NCT03345901
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 11, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - ENRGy2 Addendum

NCT01764373
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Aerobic Exercise
Other
Lead sponsor
University of Kansas
Other
Eligibility
40 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Jun 11, 2026, 12:54 AM EDT